SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CRII - Cell Robotics International, Inc. -- Ignore unavailable to you. Want to Upgrade?


To: michael b greenberg who wrote (195)3/22/1999 3:39:00 PM
From: WallStBum  Respond to of 252
 
Not CRII but interesting related news release:

New 'No-Strip' Blood Glucose Meter Encourages People with Diabetes to Test More [.20328]

/FROM PR NEWSWIRE NEW YORK 800-776-8090/
TO BUSINESS AND MEDICAL EDITORS:

New 'No-Strip' Blood Glucose Meter Encourages People with
Diabetes to Test More Frequently

Studies Support Important Benefits of Frequent Testing

TARRYTOWN, N.Y., March 22 /PRNewswire/ -- Bayer Corporation, Diagnostics
Division today announced the U.S. availability of the Glucometer(R) DEX(R)
Diabetes Care System, America's only "no-strip" blood glucose meter that
allows people with diabetes to perform 10 tests with a single cartridge stored
in the meter. This eliminates the need to carry and handle separate test
strips when testing blood glucose levels. With this added convenience, the
Glucometer DEX System represents a significant advance for the nearly 16
million people with diabetes, for whom frequent monitoring is recommended to
help reduce serious health complications, such as cardiovascular disease,
kidney disease and blindness.
"Frequent blood glucose monitoring is critical to better control," said
Robin Goland, M.D., director of the Naomi Berrie Diabetes Center at Columbia
Presbyterian Medical Center, New York. "When patients are more aware of their
blood sugar levels, they are able to more accurately adjust their diet,
exercise routine and treatment, thus reducing complications."

Largest Trial to Date Suggests Increased Testing with Glucometer(R)
DEX(R) System
In a study of over 14,400 Glucometer DEX meter users and 2,900 health
professionals -- the largest ever multi-center home meter trial -- almost
two-thirds (63%) of those who tested their blood sugar fewer than three times
a day predicted they would test more often with the Glucometer DEX System.
Almost one-third of all Glucometer DEX System users predicted more frequent
testing.
Nearly eight out of over 10 users preferred the new Glucometer DEX System
over their current blood glucose monitors, and 86% of healthcare professionals
predicted their patients would test more frequently with the Glucometer DEX
System.
In addition, the online resource Children with Diabetes
(http://www.childrenwithdiabetes.com), gave the Glucometer DEX System a rating
of "highly recommended," awarding perfect scores in ease of use, monitor
features, and suitability for use by children.

Survey Supports Mounting Evidence that Frequent Testing Facilitates
Control
Controlling diabetes is more important to people with diabetes than other
important lifestyle issues, such as having time for family and friends and
surprisingly, even career or job performance, according to a new Roper Starch
Worldwide survey of 427 people with diabetes who monitor their blood sugar.
More than 90% of the participants agreed that testing their blood sugar gives
them a better sense of control over their lives. In fact, of all the measures
the respondents take to keep their diabetes under control, such as following a
strict diet, exercise and visiting the doctor, blood sugar testing was rated
the most important.
The survey also showed that the degree to which people control their
diabetes has a profound effect on their outlook on life, ability to cope with
the disease, and the extent to which they worry about life-threatening
complications. For example:

-- Those with better metabolic control of diabetes cope better emotionally
with the disease. Eighty percent of those in control said they are
coping extremely or very well vs. only 56% of those not in control.
-- People with diabetes who do not test their blood sugar daily and whose
disease is not in control worry more that the disease could be fatal.
This concern is also more prevalent among the youngest group of
respondents, ages 22-33.
-- When respondents were asked what they would do if their diabetes were
under control, most (45%) said they would take an exotic vacation.
Other responses included "have an intimate or sexual relationship" and
"be more romantic."
-- By a significant margin, more males than females said they would have
an intimate relationship or be more romantic.

The Glucometer DEX System has several complementary features in addition
to a 10-test cartridge. The device uses "sip-in" technology to draw a small
amount of blood (3-4 microliters) into the test sensor. The Glucometer DEX
System produces results in just 30 seconds and can show results of the user's
two most recent tests, a two-week average of test results, time-specific
averages and individual test results. With an electronic memory, the
Glucometer DEX Meter stores up to 100 test results. The WinGlucofacts(TM)
software program allows users to transfer test results to a personal computer
to log, summarize and calculate averages from all test results.
Bayer Corporation, Diagnostics Division, headquartered in Tarrytown, NY,
(http://www.bayerds.com) is the U.S. member of Bayer's Business Group
Diagnostics -- one of the largest diagnostics businesses in the world. The
company serves customers in 100 countries with an offering that includes
diagnostics systems in three key segments: Laboratory Testing, Point of Care
Testing and Self Testing. Bayer Diagnostics has approximately 8,000 employees
worldwide with combined 1997 sales of close to $1.7 billion. Bayer
Diagnostics is a member of the worldwide Bayer Group, a $32 billion chemical
and pharmaceutical company based in Leverkusen, Germany.

SOURCE Bayer Corporation

/CONTACT: Laura Kaplow of BSMG Worldwide, 212-445-8119, for BayerCorporation/

/Web site: bayerds.com

Mar-22-1999 14:31 GMT
Source PRN PR NewsWire
Categories:
NWR/NY NWI/MTC NWS/PDT



To: michael b greenberg who wrote (195)3/22/1999 3:47:00 PM
From: WallStBum  Read Replies (1) | Respond to of 252
 
I was checking out the link to childrenswithdiabeties that was in that release. There was some discussion of these rumored continuous glucose level monitors. I came across the following and wonder if there are negative or postive implications for CRII:

MiniMed Inc. Announces Unanimous Conditional Recommendation Of FDA Panel For Continuous Glucose Monitoring System To Treat Diabetes
--------------------------------------------------------------------------------


Sylmar, California, February 26, 1999 - MiniMed Inc. (Nasdaq: MNMD) today announced that a Food and Drug Administration (FDA) Advisory Panel has issued a conditional recommendation for agency approval of MiniMed's premarket approval application (PMA) for a system designed to provide continuous glucose monitoring for people with diabetes. The Panel has unanimously recommended that the FDA approve the PMA, subject to the satisfaction of certain pre-market, post-market and labeling conditions.

MiniMed's PMA relates to a physician monitor product to be used as a tool in treating patients with diabetes, much like a cardiac Holter-style monitor. MiniMed's continuous glucose sensor is designed to be inserted into the subcutaneous tissue, usually in the abdominal area, utilizing a soft cannula type device.

Commenting on the announcement, Alfred E. Mann, MiniMed's Chairman and CEO, stated, "We are pleased with the Panel's unanimous action today and intend to begin addressing the Panel's recommendations and conditions immediately." Terrance H. Gregg, President and Chief Operating Officer, added, "We are appreciative of these recommendations and look forward to providing another tool to advance the state of diabetes care."

MiniMed Inc. designs, develops, manufactures and markets advanced infusion systems with a primary emphasis on the intensive management of diabetes. The Company's products include external pumps and related disposables, as well as the distribution of an implantable insulin pump, which is currently approved for sale in the European Community and has not yet been cleared for marketing in the U.S. The Company also distributes other diabetes supplies and pharmaceutical products. The Company has submitted an application for marketing clearance for a system designed to continuously monitor glucose levels, is preparing to introduce other continuous glucose monitoring system products, and is developing new infusion systems to deliver compounds designed to treat a variety of medical conditions.

Any statements made by MiniMed in this press release that are forward-looking, including statements relating to the ability to complete successfully the clinical research activities relating to MiniMed's continuous glucose monitoring system, the ability to obtain regulatory approval with respect to any continuous glucose monitoring system product and the commercial market for MiniMed's continuous glucose monitoring system products are made pursuant to the Safe Harbor provisions of the Private Securities Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties which may affect MiniMed's business and prospects, including changes in economic and market conditions, acceptance of MiniMed's products by the health care and reimbursement communities, health care legislation, new developments in diabetes therapy, administration and regulatory approval and related considerations, and other factors discussed in the Company's filings with the Securities and Exchange Commission.

####

For:
MiniMed Inc. (818) 362-5958
Terrance H. Gregg
President and Chief Operating Officer

Kevin R. Sayer
Senior Vice President and Chief Financial Officer

Morgen-Walke Associates
Investor Releations:
Robert P. Jones/Meredith Pudalov: (212) 850-5600

Media:
Sheryl Seapy/Amanda Christensen: (415) 296-7383